Cancer Advisor

Abstract Background Repurposed antiparasitic agents including Ivermectin, Fenbendazole, and Mebendazole have gained substantial public attention as potential adjunctive therapies for colorectal cancer. Online compilations of anecdotal reports have expanded rapidly following social media amplification, celebrity endorsements, and physician-curated testimonial series. ( onedaymd.com ) Objective To systematically reorganize and critically analyze 79 published colorectal cancer case reports and testimonials involving ivermectin-, fenbendazole-, or mebendazole-based regimens, with emphasis on tumour biology, metastatic patterns, regimen heterogeneity, evidence hierarchy, and potential sources of bias. Methods A structured qualitative evidence-mapping analysis was conducted using publicly available case reports and testimonials compiled in a widely circulated colorectal cancer review article published by OneDayMD. Cases were stratified by cancer subtype, disease stage, metastatic distrib...

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal cancers worldwide. With a 5-year survival rate of only 13% (American Cancer Society, 2026 data) and dropping to 3% for metastatic disease, PDAC has seen little improvement in outcomes over the past decades. Late diagnosis, dense tumor stroma, and near-universal KRAS mutations (90-95% of cases) drive rapid resistance to standard chemotherapy. Most patients are diagnosed at advanced stages, and resistance to chemotherapy develops rapidly. However, 2025–2026 has brought an unprecedented wave of breakthroughs that may finally shift the landscape of pancreatic cancer treatment.  A landmark triple drug therapy for pancreatic cancer, detailed in a December 2025/January 2026 study published in  Proceedings of the National Academy of Sciences  (PNAS) by researchers at Spain’s National Cancer Research Centre (CNIO), has delivered unprecedented preclinical results: complete tumor eradication in multiple...